[Dyslipidemia and obesity 2011. Similarities and differences]

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease
• Public Health

Background:

• Hyperlipoproteinemia (HLP/DLP) and obesity are prevalent metabolic diseases affecting a significant portion of the population.
• While distinct, HLP/DLP and obesity frequently co-occur, influenced by lifestyle and potentially genetic factors.
• Obesity is known to exacerbate lipid metabolism issues in individuals with genetically predisposed HLP/DLP.

Purpose of the Study:

• To review the associations and distinctions between hyperlipoproteinemia (HLP/DLP) and obesity.
• To explore their shared risk factors and common complications, particularly cardiovascular diseases and metabolic syndrome.
• To discuss current and emerging therapeutic strategies targeting both conditions.

Main Methods:

• Literature review focusing on the relationship between HLP/DLP and obesity.
• Analysis of epidemiological data on the incidence and co-occurrence of these metabolic diseases.
• Examination of pharmacological and surgical interventions for managing HLP/DLP and obesity.

Main Results:

• HLP/DLP and obesity are high-incidence metabolic diseases often linked by unhealthy lifestyles and genetic predispositions.
• Both conditions are significant risk factors for cardiovascular diseases, often occurring together within the metabolic syndrome.
• Pharmacotherapies like metformin, pioglitazone, and incretins (e.g., liraglutide), along with bariatric surgery, show promise in managing lipids and body weight.

Conclusions:

• HLP/DLP and obesity, while separate, share common pathways and significantly increase cardiovascular risk, especially when part of metabolic syndrome.
• Integrated therapeutic approaches addressing both lipid profiles and body mass index are crucial for effective patient management.
• Emerging pharmacological agents and bariatric surgery offer promising avenues for improving outcomes in patients with co-existing HLP/DLP and obesity.